Medtronic Upgraded at UBS on Diabetes Turnaround
TD Cowen Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $381
Jefferies Adjusts Merck & Company Price Target to $147 From $150
HSBC Adjusts Price Target on Eli Lilly and Co. to $1,150 From $1,100, Maintains Buy Rating
Eli Lilly Analyst Ratings
Daiwa Securities Adjusts Price Target on Eli Lilly and Co. to $940 From $800, Maintains Outperform Rating
Berenberg Bank Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $1,050
Berenberg Bank Reaffirms Their Buy Rating on Eli Lilly & Co (LLY)
DBS Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $1,060
Leerink Partners Maintains Johnson & Johnson(JNJ.US) With Buy Rating
Jefferies Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $150
Morgan Stanley Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Maintains Target Price $169
Daiwa Securities Adjusts Price Target on Amgen to $351 From $350, Maintains Buy Rating
Don't Forget This Startup's Weight-Loss Pill, Analyst Says -- Barrons.com
Why Eli Lilly Is a Buy After Earnings. The Stock Got an Upgrade. -- Barrons.com
AbbVie Analyst Ratings
Eli Lilly Analyst Ratings
Morgan Stanley Adjusts Price Target on AbbVie to $218 From $211, Maintains Overweight Rating
Barclays Remains a Buy on Eli Lilly & Co (LLY)
Redburn Atlantic Adjusts Amgen Price Target to $180 From $170, Maintains Sell Rating